When was Hemab founded?

Hemab was founded in 2019 and raised its 1st funding round 1 year after it was founded.

Where is Hemab located?

Hemab is headquartered in Copenhagen, Denmark.

Which legal entities is Hemab associated with?

Hemab is associated with Hemab ApS and 1 other.

How many employees does Hemab have?

As of Jul 31, 2026, the latest employee count at Hemab is 99.

Is Hemab a funded company?

Hemab is a funded company, having raised a total of $310M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Nov 20, 2020.

When was the latest funding round of Hemab?

Hemab's latest funding was a $***** Series C round on Oct 27, 2025, with participation from 10 investors.

What is the annual revenue of Hemab?

Annual revenue of Hemab is between undefined and undefined as on Dec 31, 2022

Where does Hemab rank among its competitors?

Hemab ranks 427th amongst 2479 active competitors, of which 851 are funded. It stands 2nd in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Hemab?

Hemab's top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Among them, Immuneel secured the most recent funding round in June, 2026.

Hemab - 2026 Company Profile, Funding, Competitors & Financials

Company Details

Developer of preventative treatments for rare bleeding and thrombotic disorders. It develops novel therapies designed to modulate the body's clotting pathway, using antibodies to either stabilize or inhibit clotting factors. This approach addresses a significant unmet need for patients with less common disorders, offering prophylactic treatments and potential functional cures to prevent life-threatening complications. The company's pipeline includes several therapeutic candidates targeting various rare clotting disorders.

Website: www.hemab.com/
Email ID: *****@hemab.com

Key Metrics

Founded Year

2019

Location

Copenhagen, Denmark

Stage

Public

Total Funding

$310M in 4 rounds

Latest Funding Round

Series C, Oct 27, 2025, $*****

Investors

Access Industries & 9 more

Ranked

427^th among 2479 active competitors

Annual Revenue

as on Dec 31, 2022

Employee Count

99 as on Jul 31, 2026

Similar Companies

STAR Therapeutics & 81 more

Exit Details

Public

View Hemab's full profile

Hemab is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Hemab ApS CIN: 40837590 , Denmark, Active	Sep 27, 2019	-	-
Hemab ApS CIN: 40837590 , Denmark, Active	Sep 26, 2019	(As on Dec 31, 2022)	18 (As on Feb 29, 2024)

Hemab got listed on May 01, 2026.

Click here to take a look at Hemab's IPO in detail

Hemab has raised a total funding of $310M over 4 rounds. Its first funding round was on Nov 20, 2020. Its latest funding round was a Series C round on Oct 27, 2025 for $*****. 10 investors participated in its latest round. Hemab has 10 institutional investors.

Here is the list of recent funding rounds of Hemab:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Oct 27, 2025	9189855	Series C	9856484	9153574	8553599	8834238
Feb 21, 2023	6485850	Series B	5589151	5989767	3081140	Deep Track Capital & 7 more
Jul 22, 2021	2584337	Series A	1004922	6231855	Novo Holdings & 2 more	4179134

Access funding benchmarks and valuations. Sign up today!

View details of Hemab's funding rounds and investors

Hemab's employee count trend

Hemab has 99 employees as of Jul 26. Here is Hemab's employee count trend over the years:

Uncover Hemab's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Hemab include Jazz Pharmaceuticals, Sana Biotechnology and Ideaya Biosciences. Here is the list of Top 10 competitors of Hemab, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
3rd	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	73/100
4th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, Alta Partners & 17 others	72/100
5th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
6th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	72/100
7th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, F-Prime Capital & 23 others	71/100
8th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
9th	Zymeworks 2003, Vancouver (Canada), Public	Developer of bi-specific antibodies & antibody-drug conjugates to treat cancer	$146M	CTI Life Sciences Fund, Advanced Biotechnologies Venture Fund ... & 17 others	71/100
10th	Erasca 2018, San Diego (United States), Public	Developer of small molecule based therapeutics for cancer	$300M	Cormorant Asset Management, Arch Venture Partners ... & 13 others	71/100
427th	Hemab 2019, Copenhagen (Denmark), Public	Developer of preventative treatments for rare bleeding and thrombotic disorders	$310M	Access Industries, Avoro Capital & 8 others	51/100